Jefferies has set a $17 price target for Freenome, indicating a potential 47% upside from its recent close at $11.56. This forecast suggests strong growth potential as Freenome launches its cancer screening tests, making it an attractive option for investors seeking opportunities in the biotech sector.
Key Highlights
- Freenome shares surged over 12% to close at $13.00 following Jefferies' initiation of coverage.
- The company received a $100 million milestone payment from Abbott for FDA clearance of its colorectal cancer test.
- Freenome's projected Revenue is about $34 million, with a Market Value around $1.3 billion.
Jefferies Coverage Sparks Investor Interest
Freenome's stock saw a significant uptick following Jefferies analyst Tycho Peterson's initiation of coverage with a $17 price target. This valuation implies a potential increase of approximately 47% from Freenome's previous closing price of $11.56. Investors responded to this bullish guidance with enthusiasm, adopting a strong buying sentiment that propelled shares over 12% to close at $13.00.
The positive reaction underscores the market’s growing interest in Freenome’s innovative cancer diagnostics, especially as the company transitions from a research entity to a commercial powerhouse. This transition is critical as it marks the beginning of Freenome’s potential to capture Market Share in the oncology screening sector.
Expanding the Cancer Screening Portfolio
Freenome is pioneering blood-based cancer tests, starting with its SimpleScreen colorectal cancer test, set to compete against established alternatives like Exact Sciences' Cologuard. The company’s Partnership with Abbott, which received a substantial $100 million milestone payment upon FDA clearance of the test, positions Freenome for a strategic advantage. In addition to this, Freenome is looking to expand into multiple cancer types, significantly enhancing its revenue streams and market presence.
However, the success of this growth strategy hinges on adoption rates among healthcare providers and patients, which could shape the company’s future performance.
FDA Partnerships and Milestones
Freenome has garnered support from key partners, including Roche, which provides international market access and exclusive rights for developing integrated versions of its tests. Analysts see these partnerships not just as financial backing but as essential pathways to market penetration, with an emphasis on the royalties and milestone payments that could generate value for shareholders. The optimistic trajectory for Freenome involves meeting important regulatory benchmarks, particularly as they prepare for the FDA's review of upcoming tests, including a lung cancer screening.
Success in these ventures could further elevate the stock's attractiveness to investors.
Managing Future Regulatory Hurdles
While Jefferies provided an optimistic outlook with a $17 price target, several critical milestones must be achieved to validate this growth projection. The upcoming U.S. Preventive Services Task Force review, expected in late 2027 or 2028, will be important for determining Medicare and private insurance coverage for Freenome's colorectal test. If the task force recommends the test, wider adoption could follow, significantly boosting revenues.
Additionally, Freenome's lung cancer test, with its recent Breakthrough Device Designation from the FDA, represents a key next step. However, the company remains in the early stages of commercialization, which brings inherent risks that could impact its financial viability. Investors should stay attuned to these developments, given that the stock’s trajectory hinges on successful market entry and acceptance of its innovative testing technologies.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...